Page 128 - 《中国药房》2025年7期

patients with ulcerative colitis treated with etrasimod，and heart allografts[J]. Circulation，2005，111（2）：222-229.
association with faecal calprotectin and C-reactive pro‐ [43] PÉREZ-JELDRES T，TYLER C J，BOYER J D，et al. Tar‐
tein：results from the phase 2 OASIS trial[J]. J Crohns geting cytokine signaling and lymphocyte traffic via small
Colitis，2024，18（6）：885-894. molecules in inflammatory bowel disease：JAK inhibitors
[35] SANDBORN W J，VERMEIRE S，PEYRIN-BIROULET and S1PR agonists[J]. Front Pharmacol，2019，10：212.
L，et al. 968a：etrasimod 2 mg once daily as treatment for [44] SONG J H，MATSUDA C，KAI Y，et al. A novel sphingo‐
moderately to severely active ulcerative colitis：results sine 1-phosphate receptor agonist，2-amino-2-propanediol
from the phase 3 elevate UC 52 and elevate UC 12 trials hydrochloride （KRP-203），regulates chronic colitis in in‐
[J]. Gastroenterology，2022，162（7）：S-1395. terleukin-10 gene-deficient mice[J]. J Pharmacol Exp
[36] TAYLOR C L，CHIOREAN M，VERMEIRE S，et al. Etra‐ Ther，2008，324（1）：276-283.
simod improves quality of life in adults with moderate-to- [45] RADEKE H H，STEIN J，VAN ASSCHE G，et al. A multi‐
severe ulcerative colitis[J]. Gut，2022，71：A143. centre，double-blind，placebo-controlled，parallel-group
[37] SIEGMUND B，KOMORI H K，ABREU M T，et al. Ef‐ study to evaluate the efficacy，safety，and tolerability of
fect of etrasimod on immune cell subsets in colonic tissue the S1P receptor agonist KRP203 in patients with modera-
of patients with ulcerative colitis：immunophenotyping tely active refractory ulcerative colitis[J]. Inflamm Intest
analysis of colon biopsy samples from the phase 3 elevate Dis，2020，5（4）：180-190.
UC 52 and elevate UC 12 trials[J]. J Crohns Colitis，2023， [46] GROVES A，KIHARA Y，CHUN J. Fingolimod：direct
17（Suppl. 1）：i701-i704. CNS effects of sphingosine 1-phosphate （S1P） receptor
[38] PEYRIN-BIROULET L，DUBINSKY M C，SANDS B E， modulation and implications in multiple sclerosis therapy
et al. Efficacy and safety of etrasimod in subjects with [J]. J Neurol Sci，2013，328（1/2）：9-18.
moderately to severely active isolated proctitis：a sub‐ [47] YANG J，GUAN X，HE S M，et al. FTY720 attenuates
group analysis of the phase 3 ELEVATE UC 52 and acute colitis via colonic T cells reduction and inhibition of
ELEVATE UC 12 trials[J]. J Crohns Colitis，2023，17 M1 macrophages polarization independent of CCR2-
（Suppl. 1）：i536-i538. mediated monocytes input[J]. Int Immunopharmacol，
[39] SHIMANO K，MAEDA Y，KATAOKA H，et al. Amiseli‐ 2023，123：110731.
mod （MT-1303），a novel sphingosine 1-phosphate recep‐ [48] MAKLED M N，SERRYA M S，EL-SHEAKH A R. Fingo‐
tor-1 functional antagonist，inhibits progress of chronic limod ameliorates acetic acid-induced ulcerative colitis：
colitis induced by transfer of CD4 CD45RBhigh T cells an insight into its modulatory impact on pro/anti-
+
[J]. PLoS One，2019，14（12）：e0226154. inflammatory cytokines and AKT/mTOR signaling[J].
[40] SUGAHARA K，MAEDA Y，SHIMANO K，et al. Amise‐ Basic Clin Pharmacol Toxicol，2022，130（5）：569-580.
limod，a novel sphingosine 1-phosphate receptor-1 modu‐ [49] KOMIYA T，SATO K，SHIOYA H，et al. Efficacy and im‐
lator，has potent therapeutic efficacy for autoimmune di- munomodulatory actions of ONO-4641，a novel selective
seases，with low bradycardia risk[J]. Br J Pharmacol， agonist for sphingosine 1-phosphate receptors 1 and 5，in
2017，174（1）：15-27. preclinical models of multiple sclerosis[J]. Clin Exp Im‐
[41] D’HAENS G，DANESE S，DAVIES M，et al. A phase Ⅱ， munol，2013，171（1）：54-62.
multicentre，randomized，double-blind，placebo-controlled [50] SANADA Y，MIZUSHIMA T，KAI Y，et al. Therapeutic
study to evaluate safety，tolerability，and efficacy of amise‐ effects of novel sphingosine-1-phosphate receptor agonist
limod in patients with moderate to severe active Crohn’s W-061 in murine DSS colitis[J]. PLoS One，2011，6（9）：
disease[J]. J Crohns Colitis，2022，16（5）：746-756. e23933.
[42] SHIMIZU H，TAKAHASHI M，KANEKO T，et al. KRP- （收稿日期：2024-11-28 修回日期：2025-02-28）
203，a novel synthetic immunosuppressant，prolongs graft （编辑：唐晓莲）
survival and attenuates chronic rejection in rat skin and

· 886 · China Pharmacy 2025 Vol. 36 No. 7 中国药房 2025年第36卷第7期